A limited number of studies have investigated the estrogenic potential of acetaminophen but none has reported its effects on breast cells. Many compounds that alter estrogen-mediated processes in various tissues contain p-phenolic moieties. Acetaminophen is a commonly used analgesic/antipyretic that also contains a p-phenol. This study tested the hypothesis that therapeutic concentrations of acetaminophen alter estrogen-responsive human breast cancer cell DNA synthesis. To this end, a modified E-screen assay was developed to determine the response to acetaminophen of two dichotomous types of human breast cancer cell lines: estrogen-responsive (MCF7, T47D, ZR-75-1) and estrogen-nonresponsive (MDA-MB-231, HS578T). Cells were placed in estradiol-free medium and then exposed to 3 nM estradiol or 0.03-1 mM acetaminophen. The proliferative response was assessed by determining [ 3 H]thymidine incorporation into DNA and by determining the percentage of cells in the DNA synthesis (S) phase of the cell cycle. Concentrations of acetaminophen commonly attained in human plasma with therapeutic doses of this drug (~0.1 mM) were found as effective as estradiol in stimulating DNA synthesis in estrogen-responsive breast cancer cells. Higher acetaminophen concentrations (1 mM) stimulated estrogen-responsive cells to a lesser extent The combination of estradiol and acetaminophen did not stimulate DNA synthesis in estrogen-responsive cells more than either agent alone. Neither acetaminophen nor estradiol stimulated DNA synthesis in estrogen-nonresponsive human breast cancer cells. These novel findings demonstrate that therapeutic acetaminophen concentrations specifically stimulate estrogen-responsive breast cancer cell DNA synthesis, suggesting that this drug may exert estrogenic effects, c iws society of Tatkotosr.
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Xenoestrogens are chemicals that modify normal estrogen functions (Raloff, 1993) . Xenoestrogens can have stimulatory effects in estrogen-responsive target tissues/cells by mimicking estrogen action (Vohrerr, 1967) . Evidence indicates that environmental xenoestrogens may decrease reproductive capacity as well as induce feminization in males in various nonmammalian species including fish (White et al, 1994) , reptiles (Guillette el al, 1994) , and birds (Fry et al, 1987) . Exposure to polychlorinated biphenyls (PCB) may also disrupt reproductive functions in various mammalian species (Birnbaum, 1994; Colbom et al., 1993; Bergeron et al, 1994; McLachlan et al, 1993) , including whales (Martineau et al, 1988) and seals (Reijnders, 1986) . Sex-related disorders can also be induced by exposing laboratory animals to xenoestrogens (IARC, 1979) . For example, bisphenol A which leaches out from food packaging and plastic materials (Krishnan et al, 1993) produces adverse reproductive effects in rats and mice (Knaak and Sullivan, 1966; Bond et al, 1980; Atkinson and Roy, 1995) . Natural and synthetic xenoestrogens cause different types of cancer, depending on the nature, strain, and species of the tested animal (IARC, 1979) . Noble rats exposed to estrone develop breast, ovarian, uterine, bladder, testicular, lymphatic, and prostatic tumors; hamsters develop kidney and uterine tumors; rabbits develop endometrial tumors; and dogs develop breast and ovarian tumors (IARC, 1979; Ofner et al, 1992) . Although still controversial, recent epidemiological studies have lead to a concern that exposure to xenoestrogens may be involved in the etiology of some human cancers and other health problems (Safe, 1995) . For example, exposure to diethylstilbestrol may be involved in breast cancer development (Wolf et al, 1993; Malone, 1993) .
Some Pharmaceuticals, such as estradiol and diethylstilbestrol (estrogenic prototypes), ethynylestradiol, equilenin, and mestranol were designed to exploit their estrogenic potential (Roy et al, 1997) . However, cimetidine and digitalis are examples of drugs that have not been designed for estrogenicity and yet display this potential (Roy et al, 1997) . Xenoestrogens have diverse chemical structures and structure-activity correlations are difficult to establish (Duax and Weeks, 1980) . However, a minimal chemical structure resemblance with estrogen seems sufficient for estrogenicity (Cunningham et al, 1997) . For the xenoestrogens depicted in Fig. 1 , a common structural characteristic is the p-phenol moiety. Many ^-phenolic environmental chemicals are weak xenoestrogens (Roy et al., 1997) .
The present study focuses on acetaminophen, which contains a phenol ring, like estradiol, and a p-acetyl group, like progesterone ( Fig. 1) . Thus, acetaminophen may have a sex steroid agonistic or antagonistic effect, depending on the cell types on which it acts (Cramer et al., 1998) . This drug is found in many frequently used analgesic/antipyretic medications (Kastrup, 1981) . Only a limited number of studies have reported on aspects of the potential estrogenic or antiestrogenic activity of acetaminophen in estrogen-responsive tissues/cells. We know of no studies examining acetaminophen effects on breast cancer cells. Acetaminophen (5-50 /i-g/kg) did not compete with binding of estradiol to mouse uterine estrogen receptors, and it tested negative in a mouse uterotrophic bioassay (Isenhowenera/., 1986) . Other studies (Reel et ai, 1992; Boyd, 1970) found that high acetaminophen doses (1.43 mg/kg/day) in mice reduced the number of litters per breeding pair, increased the percent abnormal sperm, and increased testicular atrophy. The differences in acetaminophen doses used in these two studies may account for the different effects observed. Neither study reported acetaminophen plasma levels, making it difficult to relate the significance of these studies to pharmacological levels achieved in humans. In other studies, acetaminophen reduced progesterone production in porcine granulosa cells (Haney et ai, 1987) and inhibited estrogen-induced vitellogenin production in trout liver cells (Miller et al., 1998) .
A recent study (Cramer et ai, 1998) reported that daily acetaminophen use in humans decreased risk of ovarian cancer. The mechanisms by which acetaminophen may cause the variety of effects observed are not yet known, but, depending on the dose used, may involve toxicity, inhibition of cyclooxygenase, and/or sex steroid agonistic or antagonistic properties.
This study tested the hypothesis that acetaminophen alters DNA synthesis in estrogen-responsive human breast cancer cells in vitro. Human breast cancer cells in culture provide a well-established in vitro test system (Adams, 1988) frequently used to initially assess if various compounds exhibit estrogenic or antiestrogenic properties (Soto et ai, 1995) . The E-screen assay designed by Soto et al. (1995) involved one type of estrogen-responsive breast cancer cell line (MCF7). This study developed a modified E-screen assay utilizing multiple cell lines within two dichotomous groups of breast cancer cells (estrogen receptor positive, ER + , and estrogen receptor negative, ER~) and two different endpoints that reflect cell proliferation ([ 3 H]thymidine incorporation into DNA and the percentage of cells in the S phase of the cell cycle). The modified E-screen assay was designed to assure consistency in terms of dichotomy of response. In addition, many breast tumors are heterogeneous and different from patient to patient. The use of multiple cell lines more accurately represents the diversity of tumors found in patients (Ceriani et al., 1992) . The cells in this study represent both major types of breast carcinoma, ductal and lobular. Experimental details are presented under Materials and Methods.
MATERIALS AND METHODS
Materials. The T47D, ZR-75-1, and HS578T cells were purchased from the American Type Tissue Collection. Dr. J. Strobl (Department of Pharmacology and Toxicology, West Virginia University) donated the MCF7 and MDA-MB-231 cells. Coming tissue culture flasks and dishes (35 X 10 mm), Whatman GF/A microfiber filters, and disposable sterile pipettes were purchased from Fisher (Pittsburgh, PA). Dulbecco's modified Eagle's medium with phenol red (DMEM) and without phenol red (PRF-DMEM), fetal bovine serum (FBS), glutamine, and gentamicin were purchased from BioWhittaker (Walkersville, MD). />-Acetamidophenol (acetaminophen), trypsin, propidium iodide, and other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
Cell culture. Cells were maintained in DMEM supplemented with 10% FBS and gentamicin. Cells were always passed before confluence was reached Prior to initiating tests, cells were depleted of estrogen by maintaining them in PRF-DMEM, supplemented with 2 % estrogen-free FBS and gentamicin for 2-4 days prior to addition of test compounds. Estrogen-free FBS was prepared using the dextran-charcoal procedure (Strobl et al., 1994) .
Experimental design.
To investigate the effects of acetaminophen on breast cancer cell DNA synthesis, a modified E-screen assay was designed to contain built-in redundancy. Two dichotomous groups of breast cancer cells (ER + and ER~) were included to assure consistency in terms of dichotomy of response (e. g., ER + cells were expected to respond to xenoestrogens, while ER~ cells were not). Multiple cell lines within each group of ER + and ERc ells assured consistency of response within each group (e.g., T47D, MCF7, and ZR-75-1 cells were expected to show similar responses). Two different end points that reflect DNA synthesis, [
3 H]thimidine incorporation into DNA and the percentage of cells in the S phase of the cell cycle, assured consistency with respect to DNA syntiiesis patterns. All cultures were depleted of estrogens as described above, and then medium was replaced daily. Medium contained no additions (negative control), 3 nM 17 p-estradiol (positive control, or 0.03-1 mM acetaminophen.
[
3 H]TJiimidine incorporation.
[ 3 H]Thimidine incorporation into newly synthesized DNA was measured as one means of assessing the effects of estradiol and acetaminophen on breast cancer cells. In each experiment, cultures were divided into seven treatment groups: (1) negative control (medium alone); (2) positive control (3 nM estradiol); (3) 3 nM estradiol + 0.1 mM acetaminophen; (4-7) 0.03 mM, 0.1 mM, 0.3 mM, and 1 mM acetaminophen, respectively. The acetaminophen concentrations ranged from therapeutic (0.03-0.1 mM) to toxic (1 mM) plasma level counterparts in humans (Forrest et al, 1982; Jensen et al, 1996) . The estradiol concentration corresponds to physiological plasma levels in women (Vohrerr, 1967) . Two milliliters of cell suspension was plated into 35-mm culture dishes. Plating densities (cells/ml) varied from 0.3 X 10 3 (estrogen-nonresponsive cells) to 1.5 X 10 3 (estrogen-responsive cells) because estrogen-nonresponsive cells proliferate faster than estrogen-responsive cells. Immediately after administering the last dose, cells were incubated with 3.6 /xCi/ml [ 3 H]thymidine (17 ftCi) for 4 h. Cells were washed with Hanks' balanced salt solution, and then 10 % trichloroacetic acid (TCA) was added to precipitate DNA. TCA was removed and the precipitate was dissolved in 1 ml 0.1 N NaOH, then reprecipitated with 1 ml 20% TCA, and subsequently filtered on to GF/A filters. The filters were rinsed with 0.1 N HC1 and then 70 % ethanol and dried. In flow cytometry studies, cultures were set up as described above, except that the cells were plated into 75-cm 2 flasks. Based on [ 3 H]thymidine incorporation data only 0.1 and 1 mM acetaminophen concentrations were selected for further testing to include one representative pharmacological and one toxic concentration. At the end of these experiments, cells were collected for flow cytometry analysis while medium was collected for LDH analysis. Cells were washed with Hanks' balanced salt solution, collected by trypsinization, and suspended in 1 ml Solution A (2 g trisodium citrate, 2 ml NP-40, 1.044 g spermine tetrahydrochloride, 0.121 g Tris dissolved in 2 liters distilled water) containing 0.03 mg trypsin/ml for 10 min. Then, 0.75 ml Solution A containing trypsin inhibitor (0.03 mg/ml) and RNase (0.08 /xg/ml) was added for 10 min, followed by 0.75 ml solution A containing propidium iodide (0.4 mg/ml) and spermine (1.16 mg/ml) for an additional 10 min. Samples were analyzed in die WVU Flow Cytometry Facility widi a fluorescence-activated cell analyzer (Becton-Dickinson Immunocytometry Systems, San Jose, CA). Results represent die percentage of cells in the S phase of me cell cycle, determined using the Modfit LT 2.0 software (Verity Software House).
Lactate dehydrogenase (LDH).
The culture medium from cells was tested for LDH release to assess general cytotoxicity using a Sigma Diagnostics kit (Cabaud and Wroblewski, 1958; Amdador et al, 1963) . Each sample was read on a Gilford response II Spectrophotometer.
Statistics. For [
3 H]thymidine incorporation experiments, a completely randomized design was set up to statistically analyze the data using one-way ANOVA. Data from single, representative experiments are expressed as means ± standard error. If P <0.05, differences among means were considered statistically significant. The means represent averages (cpm) of the triplicates within each treatment group from single experiments. For flow cytometry, experiments were repeated at least two times and representative results are shown.
RESULTS

[
3 H]Thymidine ( 3 H-dT) incorporation. Figures 2a, 2b , and 2c show the effects of acetaminophen on DNA synthesis in the ER + breast cancer cell lines MCF7, T47D, and ZR-75-1, respectively. As expected, relative to control, 3 nM estradiol increases 3 H-dT incorporation into the DNA of these cells. All of the ER + cells also respond to acetaminophen. Relative to control, 0.03 mM acetaminophen induced a small but significant increase in DNA synthesis (P < 0.05) in T47D (Fig. 2b) and ZR-75-1 cells (Fig. 2c ) but this effect was not statistically significant (P > 0.05) in MCF7 cells (Fig. 2a) . Concentrations of 0.1 mM (T47D and ZR-75-1) and 0.3 mM (MCF7) acetaminophen induced maximal increases in 3 H-dT incorporation (P <i 0.05), while 1 mM acetaminophen induced a smaller increase in 3 H-dT incorporation. For MCF7 and T47D cells, the relative DNA synthesis induced by 1 mM acetaminophen is small but significantly different from that of control (P <Z 0.05), while for ZR-75-1 this effect is not significantly different from that of control (P > 0.05). The relative magnitude of DNA synthesis induced by 0.1 mM acetaminophen (T47D and ZR-75-1) and 0.3 mM acetaminophen (MCF7) is approximately equal to that induced by 3 nM estradiol. Acetaminophen reproducibly stimulated DNA synthesis in all the ER + cells tested. However, in different experiments the relative magnitudes of acetaminophen-and estradiol-induced DNA synthesis varied somewhat (Figs. 2a, 2b, 4a, and 4b) . In T47D and ZR-75-1 cells, the 3 nM estradiol + 0.1 mM acetaminophen mixture induced an increase in DNA synthesis comparable in magnitude to that of 3 nM estradiol alone (P > 0.05). In , and (c) ZR-75-1. Cells were placed in estrogen-free PRF-DMEM and then three consecutive doses (1 dose/day) of 3 nM estradiol (E), 0.03-1 mM acetaminophen (A), 3 nM + 0.3 mM A (MCF7), or 3 nM E + 0.1 mM A (T47D; ZR-75-1) were administered (see experimental design). Incorporation of [ 3 H]thymidine ( 3 H-dT) into DNA was determined 4 h after the last dose and is reported as mean 3 H-dT incorporated into DNA (expressed in counts per minute, cpm) ± standard error of the mean. Symbols * and # indicate statistically significant differences in means (P < 0.05) relative to control and estradiol treatments, respectively. MCF7 cells, the mixture induced a DNA synthesis rate that is slightly greater than that of either estradiol alone or acetaminophen alone.
Figures 3a and 3b show the effects of estradiol and acetaminophen on the estrogen-nonresponsive breast cancer cells, MDA-MB-231 and HS578T, respectively. In these cells, neither estradiol nor acetaminophen increased DNA synthesis (P > 0.05). For MDA-MB-231 cells (Fig. 3a) , 1 mM acetaminophen significantly reduced DNA synthesis. Figures 4a, 4b , and 4c present the effects of acetaminophen and of estradiol on MCF7, T47D, and MDA-MB-231 cells, respectively. In these studies, flow cytometry was used to determine the percentage of cells in the S phase of the cell cycle. In both MCF7 and T47D cells, 0.1 mM acetaminophen alone and 3 nM estradiol alone induced an approximately twofold increase in the percentage of S phase cells relative to control cells (Figs. 4a and 4b) Figure  4c shows that neither estradiol nor acetaminophen increased the percentage of S phase cells of ER~, MDA-MB-231 cells (assessed by flow cytometry), also consistent with 3 H-dT incorporation data (Fig. 3a) .
Flow cytometry.
LDH.
Medium from flow cytometry cultures was assayed for LDH activity. None of the treatments cause significant loss of cellular LDH into medium (data not shown).
DISCUSSION
This is the first report to demonstrate that acetaminophen selectively stimulates DNA synthesis in estrogen-responsive human breast cancer cells. This conclusion is based on the observation that acetaminophen stimulated DNA synthesis in three different ER + breast cancer cells (Figs. 2 and 4) but did not stimulate DNA synthesis in two ER~ breast cancer cells (Figs. 3 and 4c) . The importance of testing multiple ER + and ER~ cell lines is illustrated by the report that /3-sitosterol stimulates T47D but not MCF7 breast cancer cell proliferation (Mellanon et al, 1996) . In addition to testing multiple ER + and ER~ cell lines, two different endpoints, 3 H-dT incorporation into DNA and the percentage of S phase cells, provided consistent responses of ER + and ER~ cells tested to both acetaminophen and estradiol. Concentrations of 0.1-0.3 mM acetaminophen stimulated both 3 H-dT incorporation into DNA and the percentage of S phase cells only in the three ER + cell lines. The ER + cell lines were similar in that they all exhibited acetaminophen-and estradiol-induced DNA synthesis. However, the magnitude of the acetaminophen-relative to the estradiol-induced DNA synthesis varied somewhat in different experiments and among the different ER + cell lines. Part of this variation may be attributed to differences between the two end points measured ( 
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.3A HS578T. Treatments and data collection occurred as described in Fig. 2 . Symbols • and # indicate statistically significant differences in means (P < 0.05) relative to control and estradiol treatments, respectively. ences among the three ER + cell lines (distribution of receptor subtypes, origin of cell lines, etc.). The concentrations of acetaminophen used in this study reflect therapeutic and toxic levels achieved in humans. The typical therapeutic adult doses of acetaminophen are 0.325-1.3 g administered every 4-6 h (Kastrup, 1981) , resulting in plasma concentrations of approximately 0.03-0.12 mM (Forrest et al., 1982) . Doses over 10 g are toxic (Kastrup, 1981) and lead to plasma concentrations of approximately 1 mM (Jensen et al., 1996) . Data in this paper demonstrate that nontoxic, therapeutic levels of acetaminophen stimulate DNA synthesis in ER + breast cancer cells. The mechanism by which acetaminophen stimulates DNA synthesis in ER + breast cancer cells is not yet known. The fact that acetaminophen stimulates DNA synthesis in ER + but not ER~ breast cancer cells may suggest that the estrogen receptor is involved in acetaminophen-induced DNA synthesis. In addition, DNA synthesis in ER + cells was stimulated to a similar extent by a 3 nM estradiol + 0.1 mM acetaminophen mixture as by estradiol alone. This also suggests that acetaminophen and estradiol may act in a similar manner to stimulate human ER + breast cancer cells. Studies in progress indicate that antiestrogens inhibit acetaminophen-induced DNA synthesis in ER + cells (unpublished data), further supporting the involvement of estrogen receptors in acetaminophen-stimulated DNA synthesis. In addition, acetaminophen was shown to inhibit estrogen-induced vitellogenin production in trout liver cells (Miller et al., 1998) . These findings provide additional support for acetaminophen interaction with estrogen receptors. Acetaminophen appears to have estrogenic effects in one system (increasing DNA synthesis in ER + human breast cancer cells) but to have antiestrogenic effects in another system (decreasing vitellogenin production in trout liver cells). These findings are consistent with other reports in which a single compound was found to exert estrogen agonistic or antagonistic effects depending on the species and tissue on which it acts. For instance, betulin and pinosylan elicit estrogenic effects in human breast cancer cells but not in trout liver cells (Mellanon et al, 1996) , while raloxifene exhibits antiestrogenic effects in human breast but estrogenic effects in human bone (Penissi, 1997) .
Treatment
Although studies discussed above suggest acetaminophen may influence some ER-mediated processes, a direct interaction of acetaminophen with ER has not been demonstrated. Acetaminophen did not show significant competition with estradiol for binding to the mouse uterine estrogen receptor (Isenhower et al, 1986) . However, the lO^fold molar excess of acetaminophen relative to estradiol in the mouse uterine estrogen receptor binding study may not have been enough to show appreciable competition with estradiol. Figures 2 and 4 (a and b) show that concentrations of 0.1-0.3 mM acetaminophen are required to achieve a response comparable in magnitude with that elicited by 3 nM estradiol. Therefore, acetaminophen is approximately lO'-fold less potent than estradiol in stimulating ER + breast cancer cell DNA synthesis. These differences in potencies between acetaminophen and estradiol are comparable in magnitude with those reported for other pphenolic compounds, which stimulate breast cancer cells (Soto et al., 1991) . The lack of acetaminophen interaction with the mouse uterine estrogen receptor may also be attributable to potential differences between estrogen receptors from different species and cell types (human breast cancer cells vs mouse uterine cells). Two distinct estrogen receptors, a and /3, have recently been identified (Paech et al., 1997 Cells were plated in estrogen-free, PRF-DMEM, and then three consecutive doses (1 dose/day) of 3 nM estradiol (E), 0.1 mM, 1 mM acetaminophen (A), 3 nM E + 0.3 mM A (MCF7), or3nME + 0.1mMA (T47D; MDA-MB-231) were administered (see experimental design). Cells were collected and analyzed 4 h after the last addition. Results are presented as the percentage of S phase cells.
ways. Acetaminophen may alter the conformation or the phosphorylation state of estrogen receptors with subsequent modulation of tyrosine kinases (Ciocca and Fanelli, 1997) or it may stimulate estrogen receptor binding to DNA regulatory regions (Dumont et al, 1996) .
Regardless of the mechanism, data reported here provide new evidence that acetaminophen interacts with cells of the endocrine system, specifically stimulating DNA synthesis in estrogen-responsive human breast cancer cells in vitro. Although these observations suggest that acetaminophen use could conceivably impact breast cancer, the profound differences between in vivo and in vitro conditions preclude such a conclusion at this time. Thorough in vivo studies must be conducted to determine if therapeutic levels of acetaminophen impact normal or cancerous breast tissue in either an adverse or beneficial manner.
After previously examining an estrogen receptor agonist (170-estradiol), several additional compounds have been evaluated in a Tier I screening battery for detecting endocrine-active compounds (EACs): an estrogen receptor antagonist (ICI-182,780, ICI), an androgen receptor antagonist (flutamide, FLUT), a testosterone biosynthesis inhibitor (ketoconazole, KETO), a 5a-reductase inhibitor (finasteride, FIN), and an aromatase inhibitor (anastrozole, ANA). The Tier I battery incorporates two short-term in vivo tests (a 5-day ovariectomized female battery and a 15-day intact male battery) and an in vitro yeast transactivation system (YTS). The Tier I battery is designed to identify compounds that have the potential to act as agonists or antagonists to the estrogen, androgen, progesterone, or dopamine receptors, steroid biosynthesis inhibitors (aromatase, 5a-reductase, and testosterone biosynthesis), or compounds that alter thyroid function. ICI administration decreased uterine estrogen and progesterone receptor number in the female battery, increased serum follicle-stimulating hormone (FSH) levels and caused spermatid retention in the male battery, and activated gene transcription in the YTS containing the estrogen receptor. FLUT administration increased uterine stromal cell proliferation in the female battery and decreased weights for all androgen-dependent tissues, induced Leydig cell hyperplasia, and caused hormonal alterations (increased testosterone (T), estradiol (E2), dihydrotestosterone (DHT), luteinizing hormone (LH), and FSH) in the male battery, and competed for binding to the androgen receptor in the YTS competition assay. In the male battery KETO decreased weights for all androgen-dependent tissues, caused hormonal alterations (decreased T and DHT and increased LH and FSH), and induced spermatid retention. FIN decreased seminal vesicle and accessory sex gland (ASG) unit weight and caused hormonal alterations (decreased DHT and increased LH, and PRL) in the male battery. KETO was judged not to affect any of the endpoints in the female battery. ANA decreased ASG unit weight and serum E2 levels in the male battery. Using the responses obtained for all the endpoints in the Tier I battery, a distinct "fingerprint" was produced for each type of endocrine activity against which compounds with unknown activity can be compared. These data demonstrate that the described Tier I battery is useful for identifying EACs. c IWS sodety of Toitoiogr.
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The development of a screening battery to detect endocrineactive compounds (EACs) is needed for several reasons. First, EACs have been implicated in producing developmental abnormalities, reproductive deficits, and cancer in both humans and wildlife (Ankley et al, 1997; Kavlock et al, 1996) . Second, there are bona fide examples of EACs producing adverse effects in humans (e.g., diethylstilbestrol) (Herbst et al, 1971; Gill et al., 1979) and wildlife (e.g., DDT) (Bitman and Cecil, 1970) . Last, the recently passed Food Quality Protection Act of 1996 (FQPA) and the Safe Drinking Water Act of 1996 (SDWA) require the United States Environmental Protection Agency (USEPA) to implement screening strategies for EACs.
As part of our research program to develop effective methods to screen for EACs, we have initiated a validation of a tiered-testing scheme using 15 model EACs (Cook et al., 1997b) . The two main goals of these studies are to test the hypothesis that distinct "fingerprints" of endocrine activity can be identified for specific EACs, and to evaluate which endpoints should be included in a final Tier I-type screen. Our Tier I testing scheme incorporates two short-term in vivo tests (a 5-day ovariectomized female battery and a 15-day intact male battery) and an in vitro yeast transactivation system (YTS) for identifying compounds that alter endocrine homeostasis. The Tier I female battery uses traditional uterotrophic endpoints coupled with additional biochemical and hormonal parameters to identify compounds that are estrogenic/antiestrogenic or modulate dopamine levels. The Tier I male battery uses organ weight measurements coupled with a comprehensive hormonal assessment to identify compounds that have the potential to act as agonists or antagonists to the estrogen, androgen, progesterone, or dopamine receptors, steroid biosynthesis inhibitors (aromatase, 5a-reductase, and testosterone biosynthesis), or 45 1096-6080/98 $25.00 Copyright O 1998 by the Society of Toxicology.
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compounds that alter thyroid function. The YTS uses three transformed yeast strains to identify compounds that bind to the estrogen, androgen, or progesterone receptors and activate or inhibit gene transcription (Coldham et al, 1997; Gaido et al., 1997; McDonnell et al., 1989; Schena and Yamamoto, 1988) . The combination of these three components, when run in parallel, provides a degree of redundancy that minimizes the possibility of false positive and negative responses when characterizing the intrinsic activity of an EAC. In our proposed tiered-testing scheme, Tier I is designed to identify EACs (i.e., intrinsic activity) and to prioritize compounds for further testing. Tiers II and HI are designed to assess a compound for its ability to produce an adverse response, followed by pharmacokinetic/pharmacodynamic modeling, in order to provide a comprehensive risk assessment (Cook et al, 1997b) . We have previously used 17/3-estradiol, the endogenous estrogen receptor agonist, to examine the usefulness of the Tier I screening battery for identifying estrogenic EACs (O'Connor et al, 1998 ). In the current study, five additional EACs have been examined using this Tier I screening battery. The test compounds included an estrogen receptor antagonist (ICI-182,780, ICI) (Wakeling et al, 1991) , an androgen receptor antagonist (flutamide, FLUT) (Neri et al., \912\ Simard et al, 1986) , a testosterone biosynthesis inhibitor (ketoconazole, KETO) (Feldman, 1986) , a 5a-reductase inhibitor (finasteride, FTN) (Rittmaster, 1994) , and an aromatase inhibitor (anastrozole, ANA) (Dukes et al, 1996) . Characterization of the responses obtained in Tier I for each of the test compounds will test the hypothesis that distinct "fingerprints" of endocrine activity can be described for model EACs. Studies are ongoing to examine the responses obtained with the remaining nine EACs to further validate this system.
MATERIALS AND METHODS
Test Materials
The following materials were obtained from the Sigma Chemical Company 
Tter I Battery Studies
Test Species
Male and female Crl:CD BR rats were acquired from Charles River Laboratories, Inc. (Raleigh, NC). Male rats were approximately 63 days old upon receipt Female rats, approximately 42 days old, were ovariectomized on the day of shipment (41 days old). Upon amval, rats were housed in stainless steel, wire-mesh cages suspended above cage boards and were fed irradiated PMI Feeds, Inc., Certified Rodent Diet No. 5002 and provided with tap water (United Water Delaware) ad libitum. Animal rooms were maintained on a 12-h light/dark cycle (fluorescent light), a temperature of 23 ± 2°C, and a relatively humidity of 50% ± 10%.
After a quarantine period of approximately 1 week, rats that displayed adequate weight gain and freedom from clinical signs were divided by computerized, stratified randomization into five groups of 20 females and five groups of 15 males so that there were no statistically significant differences among group body weight means. Within each group of 20 female rats, 14 animals were designated for biochemical/hormonal evaluation and 6 rats were designated for cell proliferation/morphometric evaluation. All male rats were designated for biochemical/hormonal evaluation.
Study Design
All rats were weighed daily and cage-side examinations were performed to detect moribund or dead rats. At each weighing, rats were individually handled and examined for abnormal behavior or appearance. All test compounds were prepared in 0.25% methylcellulose vehicle and administered by intraperitoneal injection at approximately 0900 h daily. Male rats were dosed for 15 days and euthanized on the morning of test day +15. Female rats were dosed for 4 days and euthanized on the morning of test day +5. The following compounds were used in the male and female in vivo battery: ICI (0.05, 0.25, 0.5, and 1.0 mg/kg/day), FLUT (0.25, 1, 5, and 20 mg/kg/day and 1, 5, 25, and 50 mg/kg/day, for males and females, respectively), KETO (25, 75, 125, and 150 mg/kg/day and 25, 50, 75, and 100 mg/kg/day for males and females, respectively), FIN (1, 5, 10, and 25 mg/kg/day), and ANA (0.1, 0.5, 0.75, and 1.5 mg/kg/day). Doses were selected in order to obtain the maximal pharmacologic effect for each compound and/or not exceed the maximum tolerated dose (MTD) as determined in range-finder studies. Due to high mortality in the 150 mg/kg/day male KETO group, data from that dose level is not reported. The dose volume was 2.0 ml/kg body wt
Cell Proliferation
Six female rats from each group were designated for cell proliferation analyses. The day prior to study start (test day -1), rats were anesthetized using isoflurane and implanted (subcutaneously) with Alzet osmotic pumps loaded with 20 mg/ml BrdU dissolved in 0.5 N sodium bicarbonate buffer. On test day +5 the rats were sacrificed and the uteri were trimmed, affixed to dental wax, fixed for 2 h in Bouin's solution, routinely processed, paraffin embedded, sectioned, and stained for immunohistochemical analysis of BrdU incorporation into DNA or sectioned and evaluated for epithelial cell height Uterine stromal cell proliferation and uterine epithelial cell height evaluation were performed as previously described (O'Connor et aL, 1996).
Estrous Conversion
Rats assigned to the biochemical/hormonal subset were evaluated for the stage of estrous by vaginal cytology. Vaginal washes were collected once daily by repeated pipetting of 75 /il of 0.9% sterile saline into the vagina. Slides were air dried and stained by the Wright-Geimsa method and evaluated for conversion out of diestrus (Davis, 1993) .
Pathological Evaluations
Female rats. Between 0700 h and 1000 h on the morning of test day +5 (approximately 24 h after the last administered dose), rats were anesthetized using CO 2 and euthanized by exsanguination. The presence of fluid in the uterine homs was recorded as a gross observation. Uteri from the biochemical/ hormonal subset were dissected, weighed, and processed to uterine cytosol for measurement of uterine progesterone and estrogen receptor content (O'Connor et al, 1996) . The thyroid glands from the biochemical/hormonal subset were placed in formalin fixative and examined microscopically. Uteri from the cell proliferation subset were dissected, weighed, and fixed in Bouin's solution. Processed tissues were embedded in paraffin, sectioned at 5 fun, and affixed to slides for staining Uterine stumps from all rats were saved in 10% neutralbuffered formalin and processed to confirm the absence of ovarian tissue by the pathologist. Blood was collected from the descending vena cava and serum prepared for hormonal analyses.
Male rats. On the morning of test day +15, rats were injected with the test compound approximately 2 h prior to sacrifice. Between 0700 h and 1000 h, rats were anesthetized using CO 2 and euthanized by exsanguination. Blood was collected from the descending vena cava and serum prepared for hormonal analyses. The liver, testes, epididymis, prostate, seminal vesicles, and accessory sex gland (ASG) unit were weighed and organ weights calculated relative to body weight The epididymis and thyroid gland were placed in formalin fixative, the left testis was placed in Bouin's fixative, and all were examined microscopically.
Hormonal Measurements
Blood was collected at the time of sacrifice from all animals. Serum was prepared and stored between -65 and -85°C until analyzed for serum hormone concentrations. For males, serum T, E2, DHT, LH, FSH, PRL, TSH, T3, and T4 levels were measured by commercially available RIA kits. For the females, serum E2 (ANA only), LH, FSH, and PRL levels were measured by commercially available RIA kits.
Uterine progesterone (PR) and estrogen (ER) receptor levels were quantitated as previously described (O'Connor et al., 1996) .
In Vitro Yeast Studies
Binding of ICI, FLUT, KETO, FIN, and ANA to the human estrogen, androgen, and progesterone receptor was examined using a yeast reporter gene system as previously described (O'Connor et al, 1998) . Receptor-specific compounds were previously used to validate this system (O'Connor et al, 1998) ; these included E2, DHT, and progesterone as die primary ligand for the three receptor systems, respectively. Briefly, yeast (Saccharomyces cerevisiae) transformants from single-plated colonies were grown overnight at 30°C with orbital shaking at 300 rpm in a selective medium containing yeast nitrogen base without amino acids plus ammonium sulfate and dextrose.
Assays were started when the cells reached an OD^,,,,,,, greateT than 1.00. One hundred microliters of cell suspension, diluted to achieve an OD^^o,,,,, of 1.00, was placed into each well of a 96-well plate and 100 /xl selective medium was added. Two microliters of each test compound, prepared in methanol, was then added to each well to develop a dose-response assay in triplicate. These cultures were incubated for 3 h at 30°C with rocking.
After incubation, cells were read at OD^o^, to evaluate the effect of the compounds on cell growth before adding 100 yX of assay buffer (60 mM Na 2 HPO 4 ,40 mM NaH 2 PO 4 , 10 mM KC1, 1 mM MgSO 4 , 2 mg/ml ONPG, 50 mM 2-mercaptoethanol, 0.1% SDS, and 200 \My.\ oxalyticase) to each well to assay for ^-galactosidase induction. The change in concentration of o-nitrophenol, the yellow product that results from /3-galactosidase activity cleaving the galactopyranoside, after a period of 1 h was determined by reading each well at 0D 410om . Nonspecific colorimetric distortions (i.e., debris) were evaluated by also reading each well at OD 37Onm .
For competitive inhibition testing of a compound, approximately a one-half maximal concentration of E2 for the YTS containing the ER or DHT for the YTS containing the AR was included in each well of the dose response for each test compound. The samples were then treated as above except that the percentage inhibition was calculated for each test compound.
Statistical Analyses
Mean final body weights and organ weights were analyzed by a one-way analysis of variance (ANOVA). When the corresponding F test for differences among test group means was significant, pairwise comparisons between test and control groups were made with Dunnett's test Bartlett's test for homogeneity of variances was performed and, when significant (p < 0.005), was followed by nonparametric procedures (Dunn's test). Serum hormone levels, progesterone and estrogen receptor levels, cell proliferation indices, and uterine morphometry measurements were analyzed using Jonckheere's test for trend. If a significant dose-response trend was detected, data from the top dose group was excluded and the test repeated until no significant trend was detected. Uterine fluid imbibition and estrous conversion data were analyzed by Fisher's test Except for Bartlett's test all other significance was judged at p < 0.05. EC50 and IC50 values were determined using a four-parameter logistic function (Origin 4.1, MicroCal Software, Inc., Northhampton, MA). EC50 values represent the concentration at which 50% of the maximal response occurred. IC50 values represent the concentration at which 50% inhibition of the response occurred.
RESULTS
In Vivo Female Battery
Final Body and Organ Weights, Uterine Fluid Imbibition, and Estrous Conversion (Table 1) Statistically significant decreases in mean final body weights were observed at the highest dosages in rats treated with FLUT or KETO (94 and 91% of control, respectively). Body weights were unchanged in rats treated with ICI, FIN, or ANA. Relative liver weights were significantly increased in rats treated with FLUT or KETO, with the greatest increase at the highest dosages (111 and 117% of control, respectively), and were unchanged in rats treated with FIN or ANA. Absolute uterine weight, uterine fluid imbibition, and estrous conversion were unchanged in rats treated with ICI, FLUT, KETO, FIN, or ANA.
Uterine Stromal Cell Proliferation and Epithelial Cell
Height (Table 2) Statistically significant increases in uterine stromal cell proliferation were observed in rats treated with FLUT, with the greatest increase at the highest dosage (294% of control), and were unchanged in rats treated with ICI, KETO, FIN, or ANA. Uterine epithelial cell height was significantly increased in rats treated with KETO, with the greatest increase at 75 mg/kg/day (144% of control), and was unchanged in rats treated with ICI, FLUT, FIN, or ANA.
Uterine Receptor Content (Data Not Shown)
Uterine cytosolic ER and PR levels were analyzed using a single saturating concentration of radiolabeled ligand. Consis- tent with previously published data (O'Connor et al., 1996) , ICI caused statistically significant decreases in both ER and PR, with the greatest decrease at the highest dosage (0 and 31% of control, respectively). Unexpectedly, FLUT, KETO, and FIN also affected uterine cytosolic receptor concentrations. FLUT and KETO caused statistically significant decreases in PR (45 and 46% of control, respectively), and FIN significantly decreased both ER and PR (50 and 68% of control, respectively). ANA did not affect ER or PR concentrations.
Serum Hormone Concentrations (Table 3)
Serum was collected for hormonal analyses approximately 24 h after the last administered dose. Statistically significant increases in serum PRL levels were observed after KETO administration, with the same magnitude increase at 75 and 100 mg/kg/day (164% of control), but were unchanged after ICI, FLUT, FIN, or ANA treatment. Serum FSH and LH were not affected by treatment with ICI, FLUT, KETO, FIN, or ANA. Serum E2 levels were not affected by treatment with ANA (data not shown), and were not measured for ICI, FLUT, KETO, or FIN.
Histopathology (Data Not Shown)
The thyroid gland was examined microscopically to identify compounds that target the thyroid gland. No microscopic changes were observed in the thyroid glands from animals treated with FLUT, KETO, FEN, or ANA. Thyroid glands from ICI-treated animals were not examined.
In Vivo Male Battery
Final Body and Liver Weights (Table 4) Statistically significant decreases in mean final body weights were observed at the highest dosage in rats treated with KETO (85% of control) and were unchanged in rats treated with ICI, FLUT, FIN, or ANA. Relative liver weight was increased in rats treated with FLUT or KETO, with the greatest increase at the highest dosages (105 and 129% of control, respectively), and was unchanged in rats treated with ICI, FIN, or ANA.
Testes and Epididymis Weights (Table 4)
Absolute testes weights were not affected by treatment with ICI, FLUT, KETO, FIN, or ANA treatment Absolute epididymis weights were significantly decreased following FLUT or KETO administration, with the greatest decrease at the highest dosages (78 and 83% of control, respectively), and unchanged after treatment with ICI, FIN, or ANA.
Accessory Sex Gland Weights (Table 4)
Relative ASG (prostate, seminal vesicles with fluid, and coagulating glands) weights were statistically significantly decreased in rats treated with FLUT, KETO, FIN, or ANA, with the greatest decrease at the highest dosages (47, 70, 51, and 80% of control, respectively). In addition, individual component weights of the ASG were also decreased after FLUT, KETO, FIN, or ANA administration, but the magnitude of the decrease did not always achieve statistical significance. For example, relative seminal vesicle weights were numerically decreased by KETO treatment, with the greatest decrease at the highest dosage (79% of control). Relative seminal vesicle weights were significantly decreased by FLUT, FIN, or ANA treatment, with the greatest decrease at the highest dosages (45, 47, and 65% of control, respectively). Relative prostate weights were significantly decreased by FLUT, KETO, or FIN treatment, with the greatest decrease at the highest dosages (56, 63, and 57% of control, respectively), and were unchanged after ANA or ICI treatment. Neither the relative ASG unit weight nor individual components of the ASG was affected by ICI treatment.
Histopathology
There were no compound-related gross lesions observed in any of the ICI treatment groups. In the testes, spermatid retention, characterized by the presence of step 19 spermatids beyond stage VHI of the cycle of the seminiferous epithelium, occurred in 0/15, 0/15, 5/15, 1/15, and 6/15 rats from the 0, 0.05, 0.25, 0.5, and 1.0 mg/kg/day groups, respectively. Sper- matid retention in the affected groups was minimal, usually involving only occasional Stage IX-XI tubules. Although not quantitatively assessed, the percentage of Stage IX-XI tubules affected was estimated to be 10-25% as compared to controls, where spermatid retention was typically less than 1%. Retained spermatids were present at the luminal margins or, less commonly, in the basilar regions of the affected tubules (Fig. 1 ). Incidences were not dose related across the 0.25 and 0.5 mg/kg groups and were not associated with other morphological changes in the testes or epididymides. Nevertheless, the finding of spermatid retention likely represents a compound-related effect based on the definitive increase in incidence (in the 0.25 and 1.0 mg/kg groups) relative to study controls, as well as to control animals from the concurrent studies that used rats of the same strain and age and the same dosing protocol.
There were no compound-related gross lesions observed in any of the KETO treatment groups. Microscopically, spermatid retention, similar to that described above for ICI, was present at the highest dosage of KETO. Incidences of spermatid retention were 1/14, 0/15,0/15, and 4/11 for animals in the 0, 25, 75, and 125 mg/kg/day dose groups, respectively. There were no microscopic changes observed in the epididymis after KETO administration.
For FLUT, small (atrophic) accessory sex glands (prostate and seminal vesicles) were present in 5/15 rats at the highest dosage. Microscopic changes were limited to interstitial cell (Leydig cell) hyperplasia in 13/15 rats in the 5 mg/kg/day group and 15/15 rats in the 20 mg/kg/day group, a finding consistent with previous data from our laboratory (unpublished data). Hyperplasia was characterized by a slight, diffuse increase in interstitial cell (Leydig cell) density (number) (Fig.  2 ). There were no microscopic changes observed in the epididymis after FLUT administration.
There were no compound-related gross or microscopic changes observed in the testes or epididymis after FIN or ANA treatment. No microscopic changes were observed in the thyroid glands from animals treated with ICI, FLUT, KETO, FIN, or ANA.
Reproductive Hormone Concentrations (Table 5)
Serum was collected for hormonal analyses approximately 2 h after the last administered dose. ICI, an estrogen receptor antagonist, caused a statistically significant increase in FSH levels, with the greatest increase at 0.5 mg/kg/day (126% of control). Serum T, E2, DHT, PRL, and LH levels were not affected by ICI treatment at dosages as high as 1 mg/kg/day.
FLUT, an androgen receptor antagonist, caused a statistically significant increase in serum T, FSH, and LH levels with the greatest increase at the highest dosage (464, 203, and 255% of control, respectively) . Secondary to the increased LH levels, serum DHT and E2 levels were significantly increased with the greatest increase at the highest dosage (343 and 163% of control, respectively). Serum PRL levels were not affected by FLUT treatment at dosages as high as 20 mg/kg/day. KETO, a steroid biosynthesis inhibitor, caused a statistically significant decrease in serum T and DHT levels, with the greatest decrease at the highest dosage (41 and 47% of control, respectively). Serum FSH and LH levels were statistically significantly increased after KETO administration, with the greatest increase at the highest dosage (163 and 194% of control, respectively). Serum E2 and PRL levels were not affected by KETO treatment at dosages as high as 125 mg/kg/day. FIN, a 5a-reductase inhibitor, caused a statistically significant decrease in serum DHT levels at all treatment groups, with the greatest decrease at 10 mg/kg/day (21% of control). Serum LH and PRL levels were statistically significantly increased, with the greatest increase at the highest dosage (138 and 135% of control, respectively). Serum T, E2, and FSH levels were not affected by FIN treatment at dosages as high as 25 mg/kg/day.
ANA, an aromatase inhibitor, caused a statistically significant decrease in serum E2 levels at all treatment levels, with the greatest decrease at 0.5 mg/kg/day (36% of control). Although not statistically significant, serum T levels were numerically decreased at all treatment levels, with the greatest decrease at 0.75 mg/kg/day (57% of control). Serum DHT, PRL, FSH, and LH levels were not affected by ANA treatment at dosages as high as 1.5 mg/kg/day.
Thyroid Hormone Concentrations (Table 6)
Thyroid hormone analyses were performed in order to evaluate the Tier I male battery for its ability to detect compounds that alter thyroid hormone homeostasis. Serum TSH, T 3 , and T 4 levels were measured. ICI caused a statistically significant decrease in T, levels, with the greatest decrease at 0.5 mg/kg/ Testosterone (ng/ml) 2.4 ± 0.6* 3.4 ± 0 9 3.6 ± 0.9 2.5 ± 0.4 1.7 ±0.3 3.6 ± 0.7 4.6 ± 1.1 6.3 ± 0.6* 9.5 ± 1.4* 16.7 ± 3.9* 2.9 ± 0.4 1.6 ±0.3* 1.2 ±0.2* 1.2 ± 0.3* 2.5 ± 0.5 2.3 ± 0.5 2.8 ± 0.4 3.9 ± 0.5 2.5 ± 0.5 3.0 ± 0.5 2.1 ± 0.5 2.2 ± 0.6 1.7 ±0.3 1.8 ± 0.5 Estradiol (pg/ml) 16.4 ± 2.8 8.4 ± 1.0 8.5 ± 1.1 8.1 ± 1.3 10.1 ± 1.1 8.9 ± 1.0 8.8 ± 1.1 7.0 ± 0.9 9.3 ± 0.7 14.5 ± 1.0* 8.7 ± 0.8 10.7 ± 0.9 11.8 ± 1.1 10.8 ± 1.2 6.2 ± 1.0 5.8 ± 1.0 6.5 ± 1.2 8.4 ± 1.5 9.1 ± 1.9 11.6 ±2.2 5.5 ± 0.7* 4.2 ± 0.5* 5.7 ± 1.1* 5.0 ± 0.8* 6.2 ± 0.9 6.5 ± 1.0 4.9 ± 0.8 3.6 ± 0.5 5.3 ± 0.6 10.1 ±2.5 9.4 ± 2.1 9.7 ± 1.4 10.5 ± 1.9 12.3 ± 2.2 6.4 ± 1.0 9.0 ± 2.8 11.2 ±2.8 8.2 ± 2.2 7.7 ± 0.9 7.5 ± 1.4 9.7 ± 1.0 9.9 ± 1.0* 10.4 ± 0.9* 7.8 ± 1.7 6.3 ± 1.1 4.2 ± 0.9 3.6 ± 0.6 5.1 ±0.9
Follicle stimulating hormone (ng/ml)'' 84.7 ± 7.2 84.4 ± 5.4 90.3 ± 6.4 106.6 ± 9.5* 102.5 ± 8.8* 20.7 ± 2.5 19.5 ± 1.3 21.8 ± 1.0 28.5 ± 1.9* 42.0 ± 3.7* 16.3 ± 1.8 15.0 ± 0.9 19.0 ± 1.2* 26.5 ±3.1* 15.9 ± 0.8 15.4 ± 0.8 16.5 ± 0.6 15.8 ± 1.1 16.5 ± 0.7 13.7 ± 0.6 13.0 ± 0. day (75% of control). Serum TSH and T 4 levels were unchanged after ICI administration.
FLUT administration caused a statistically significant decrease in serum T 3 and T 4 levels, with the greatest decrease at 5 mg/kg/day for both (76 and 67% of control, respectively). Serum TSH levels were unchanged after FLUT administration.
KETO administration caused a statistically significant increase in TSH, with the greatest increase at the highest dosage (163% of control), and a statistically significant decrease in T 3 and T 4 levels, with the greatest decrease at the highest dosage (72 and 31% of control, respectively).
FIN administration caused a statistically significant decrease in serum T 3 and T 4 levels, with the greatest decrease at the highest dosage (66 and 74% of control, respectively). Serum TSH levels were unchanged after FIN administration.
ANA administration caused a statistically significant increase in T 4 at the highest dosage (132% of control). Serum T 3 and TSH levels were unchanged after ANA administration.
In Vitro YTS
In the YTS, yeast containing a construct that expresses either the human estrogen (ER), androgen (AR), or progesterone (PR) receptors were used to evaluate various compounds for their ability to bind to the receptor and to activate a response element driving an inducible reporter (/3-galactosidase). During the testing of each compound, a positive control (E2 for ER, DHT for AR, and progesterone for PR) was included in each experiment. These positive controls served as the reference point for each day's maximum response when comparing test substances across assays, and all results were calculated as a percentage of the maximal response. No compound-related effects on growth were detected in our 3-h assay with any of the test compounds. Progesterone receptor data are not shown since none of the compounds were active in the YTS containing the PR.
Neither KETO nor ANA had activity in the YTS containing the ER (Fig. 3A) , AR (Fig. 3B) , PR (data not shown), or the ER and AR competition assay (Figs. 4A and 4B, respectively). As enzyme inhibitors, these were not expected to be active in the receptor-based YTS. ICI, an estrogen receptor antagonist, was surprisingly active in the YTS containing the estrogen receptor (Fig. 3A) , with an EC50 value of 6.6 X 1(T 5 M. Typically receptor antagonists do not activate (like an agonist) receptorbased systems; however, the YTS system has previously been Thyroid-stimulating hormone (ng/ml) 24.1 ± 1.9°2 2.8 ± 2.7 19.5 ± 1.7 20.3 ± 1.8 24.6 ± 2.9 15.2 ± 1.6 13.8 ± 1.5 18.3 ± 2.0 16.7 ± 2.2 17.1 ± 1.8 15.4 ± 1.4 20.0 ± 1.6 21.1 ± 1.6* 25.1 ± 3.6* 14.5 ± 0.9 12.0 ± 0.7 15.8 ± 1.3 14.7 ± 1.4 14.8 ± 2.2 18.2 ± 1.4 17.5 ± 1.5 23.5 ± 4.3 22.0 ± 2.0 19.5 ± 1.4
59.2 ± 2.8 56.7 ± 3.8 49.6 ± 2.8* 44.3 ±4.1* 48.6 ± 3.7* 70.9 ± 3.8 57.0 ± 3.1 65.7 ± 3.2 53.7 ± 2.9* 56.6 ± 3.4* 82.1 ± 2.8 74.6 ± 2.4 64.2 ± 4.3* 58.9 ± 5.5* 78.9 ± 3.0 68.7 ± 4.5 67.2 ± 4.3 70.5 ± 3.9 52.2 ± 3.2* 67.7 ± 2.9 60.1 ± 3.3 62.1 ± 3.4 67.5 ± 3.4 72.5 ± 4.4
T 4 (ng/dl) 2.9 ±0.1 2.6 ±0.1 2.1 ±0.1 2.6 ± 0.2 3.3 ±0.1 2.7 ± 0.3 2.5 ± 0.3 2.8 ± 0.3 1.8 ±0.2* 1.8 ±0.3* 3.5 ± 0.2 2.8 ± 0.2* 1.9 ±0.1* 1.1 ±0.2* 2.7 ± 0.2 2.8 ± 0.3 2.1 ±0.2 2.9 ± 0.2 2.0 ± 0.2* 2.8 ± 0.2 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.2 3.7 ± 0.2*° Means ± standard error. * Significantly different (p < 0.05) from control by Jonckheere's test for trend.
reported to detect compounds with agonist and antagonist activities in other systems (Gaido et al., 1997) . Interestingly, another ER antagonist, tamoxifen, was inactive in the YTS containing the estrogen receptor (Fig. 3A) , but was detected in the YTS competition assay, with an IC50 value of 3.1 X 10~4 M (Fig. 4A) . Thus, ER antagonists can be detected in this YTS system. ICI was inactive in the YTS containing the AR or PR.
The detection of androgen receptor antagonists was also possible in the YTS. FLUT, an androgen receptor antagonist, was inactive in the yeast containing the androgen receptor (Fig.  3B) ; however, in the androgen receptor YTS competition assay, FLUT competitively inhibited DHT binding to the AR (Fig. 4B) , with an IC50 value of 2.2 X 10~4 M. Interestingly, hydroxyflutamide, a metabolite of FLUT, was active in the YTS containing the androgen receptor, with an EC50 value of 8.2 X 10" 5 M (Fig. 3B) , and was also active in the YTS competition assay, resulting in an additive response (Fig. 4B) . FLUT was inactive in the YTS containing the ER or PR.
As expected, FIN, an enzyme inhibitor, was inactive in the in the YTS containing the ER (Fig. 3A) , AR (Fig. 3B ), or PR (data not shown). Surprisingly, FIN was active in both the ER (Fig. 4A) and AR (Fig. 4B ) competition assays, with IC50 values of 4.2 X 1(T 4 M and 2.4 X 10~4 M, respectively.
DISCUSSION
In this report, we have summarized the results of our ongoing Tier I screening battery using five compounds with distinct endocrine activities. We have previously described the results IG. 4. Activity of ICI-182,780, flutamide, hydroxyflutamide, finasteride, and tamoxifen in die YTS estrogen receptor (A) and androgen receptor (B) competition assay. Increasing concentrations of the test compounds were added to a YTS containing approximately one-half maximal amounts of 17$-estradiol for the estrogen receptor or dihydrotestosterone for the androgen receptor, incubated for 3 h at 30 c C, and assayed for /3-galactosidase activity after a 1-h incubation with the colorimetric substrate. The assay determined the ability of each test compound to compete with the active ligand for the receptor. Percentage inhibition was calculated.
for 17/3-estradiol using this Tier I battery (O'Connor et al, 1998) , which brings the total number of compounds evaluated to six. The two main goals of this validation are to test the hypothesis that distinct "fingerprints" of endocrine activities can be identified for each EAC and to evaluate which endpoints should be included in a final Tier I-type screen. In order to accomplish these goals, the responses observed for each of the positive controls were compared to the expected responses based on the published literature. Whenever unexpected findings were encountered, a judgement was made to distinguish between a true biologic response versus a spurious finding via searching the published literature, conducting a confirmatory experiment, or internal consistency with other components of Tier I.
Development of a "Fingerprint" for the Tier I Battery for Five Distinct Endocrine Activities
The pattern of the responses observed with ICI, a pure estrogen receptor antagonist, were characteristic of the responses expected using the described Tier I screening battery; namely, no estrogen-like responses were detected (Cook et al, 1997b) . In contrast, partial estrogen receptor antagonists (i.e., tamoxifen), produce estrogen-like responses in the in vivo female battery (O'Connor et al, 1996) . In the in vivo female battery, responses to ICI included decreased cytosolic levels of uterine estrogen and progesterone receptors with no changes in the other measured endpoints. In the uterus, estrogen treatment decreases cytosolic ER levels and increases cytosolic PR levels (Manni et al., 1981; O'Connor et al., 1996) . In the presence of an estrogen receptor antagonist, cytosolic ER levels are decreased due to nuclear retention (Manni et al., 1981; O'Connor et al., 1996) . Since PR levels are maintained by estrogen stimulus, PR levels are also decreased in the presence of an estrogen receptor antagonist (Manni et al., 1981; O'Connor et al, 1996) . In the in vivo male battery, responses to ICI included increased serum FSH levels and microscopic alterations of the testis (spermatid retention). In an intact male system, E2 acts through a central feedback loop to inhibit gonadotropin release (Knobil and Neill, 1994) . In the presence of ICI, the lack of recognition of E2 stimulates gonadotropin secretion (Knobil and Neill, 1994) . For this reason, an increase in LH was expected but was not observed. The reason for the inconsistency is unclear.
Microscopic changes following exposure to ICI were limited to minimal spermatid retention in seminiferous tubules of the testes. Spermiation is the process by which spermatids are disengaged from Sertoli cells and released into the tubular lumen (Russell et al, 1990a) . In the rat, step 19 spermatids are released in Stage VHI, although small numbers may be found in Stage IX (Hess, 1990; Russell et al., 1990b) . Delayed release of spermatids, as well as retention and phagocytosis of spermatids in the basilar Sertoli cell cytoplasm, may be observed to a minor extent in the normal rat testes (Russell et al, 1990a) . Ku and co-workers (1993) considered an incidence of retained spermatids of less than 5% to be within normal limits in adult Fischer 344 rats. Spermatid retention (delayed spermiation and failure of spermatid release) has been reported following exposure to a number of xenobiotics (Hew et al, 1993; Linder et " O'Connor et al, 1998 O'Connor et al, . al, 1994 or following hormonal deprivation (Russell et al, 1990a) . The broad spectrum of agents that have produced effects on spermiation suggests that a common mechanism of action may be involved (Hew et al, 1993) . However, whether the effect is due to abnormal phagocytic activity of the Sertoli cell (Hew et al., 1993; Treinen and Chapin, 1991) , primary abnormalities in the late step spermatids (Omura et al., 1996) , or alterations in the process of spermatid release is often not known. Spermatid retention following exposure to ICI was not clearly dose-related and was not associated with other lesions in the testes or with hormonal changes. This may indicate that the dosages used in the current study were at the threshold of the dose response for testicular effects. In a study investigating the testicular toxicity of boric acid (Ku et al., 1993) , rats were exposed to dietary concentrations of 3000 to 9000 ppm and testicular histology was performed weekly for 9 weeks. At 3000 ppm testicular changes throughout the 9-week exposure period were limited to mild inhibition of spermiation. However, with increasing dose and duration of exposure, lesions progressed from more severe inhibition of spermiation with mild germ cell exfoliation to severe testicular atrophy. Thus, the significance of the minimal spermatid retention observed following intraperitoneal exposure to ICI would likely be clarified by studies using higher exposure concentrations and/or longer durations of exposure than those used in the current study.
In the in vitro YTS, ICI activated transcription in the yeast containing the ER and was negative in the yeast containing the PR and AR. Although ICI is an estrogen receptor antagonist, it was detected using the YTS containing the ER via increased transcriptional activation. For this reason, ICI would be identified as a compound that binds to the ER, although agonist versus antagonist activity can not be distinguished as has been previously described (Gaido et al., 1997) . Other antagonists (e.g., tamoxifen) may only be detected by using a YTS competition assay. Therefore, the expected pattern for a pure estrogen receptor antagonist would be decreases in uterine estrogen and progesterone receptor levels, increases in gonadotropin levels, mild spermatid retention, and binding in the YTS containing ER (or competitive binding in the YTS competition assay) (Tables 7-9). However, the lack of specificity of uterine ER and PR levels and the body weight dependency of PR levels (i.e., PR levels decrease with decreased body weight based on dietary restriction experiments) make these data difficult to interpret (O'Connor et al, 1996) . For this reason, as well as the small increases in gonadotropin levels, positive results in the YTS would be the critical endpoint for identifying compounds that are pure estrogen receptor antagonists.
The pattern of the responses observed with FLUT, an androgen receptor antagonist, were characteristic of the responses expected using the Tier I battery. In the in vivo female battery, FLUT increased uterine stromal cell proliferation. This increase was originally unexpected. However, androgen receptor is present within the uterus; hence, the increase in uterine stromal cell proliferation is probably due to an increase in the net estrogenic stimulus within the uterus due to attenuation of the androgenic stimulus (Simard et al, 1986) . Even though an increase in uterine stromal cell proliferation is primarily a characteristic of an estrogen receptor agonist, FLUT would not have been classified as an estrogen receptor agonist due to the relatively small magnitude of the effect coupled with the other responses observed in Tier I. For example, FLUT produced a 2.9-fold increase in uterine stromal cell proliferation versus a 20-, 12-, 11-, and 14-fold increase for 17/3-estradiol, estriol, bisphenol A, and methoxychlor, respectively (Cook et al, 1997b) . Furthermore, no other estrogenic endpoints were affected by FLUT treatment. In the in vivo male battery, responses to FLUT included decreased weights for all androgendependent tissues (epididymis, seminal vesicles, prostate, and " O'Connor et al., 1998. accessory sex gland unit), hormonal alterations (increased T, E2, DHT, LH, and FSH), and microscopic changes of the testis (Leydig cell hyperplasia). FLUT, as well as its main metabolite, hydroxyflutamide, binds to the androgen receptor and effectively blocks recognition of androgens, resulting in decreased intracellular androgenic stimulus and ultimately decreased weights for the androgen-dependent tissues (Cook et al, 1993; Neri et al, 1972; Simard et al, 1986) . Centrally, there is a lack of recognition of androgens (Cook et al, 1993) . As a result of the decreased intracellular androgenic stimulus, gonadotropin release from the anterior pituitary is increased in order to stimulate T production from the Leydig cells (Neri et al, 1972; Simard et al, 1986) . In response to the increase in gonadotropins and possibly a blockade of Leydig cell androgen receptors, serum T production increases (Cook et al, 1993; Neri et al, 1972; Simard et al, 1986) . Secondary to the increase in T, serum levels of DHT (the major metabolite of T) and E2 (the aromatization product of T) also increase. The increased incidence of Leydig cell hyperplasia is a secondary effect due to the 2.5-fold increase in serum LH levels (Cook et al, 1993; Simard et al, 1986) . In the in vitro YTS, FLUT had no activity in the three receptor systems examined; however, FLUT inhibited DHT binding to the AR in the YTS competition assay. In contrast, hydroxyflutamide, a metabolite of flutamide, is detected in the YTS containing the AR, and in the YTS competition assay based on the additive effects of DHT and hydroxyflutamide. Therefore, the expected pattern for an androgen receptor antagonist would be decreases in ASG weight and hormonal alterations (increased T, DHT, LH, and FSH) in the in vivo male battery and competition for binding in the YTS competition assay containing the AR (or direct binding in the YTS assay) (Tables 7-9). Microscopic alterations of the testis (Leydig cell hyperplasia) may be observed with potent antiandrogens; however, it is unlikely that weaker antiandrogens would elicit the same response using a 15-day study duration (Cook et al, 1993 ). An apparent increase in the incidence of Leydig cell hyperplasia can occur if seminiferous tubule atrophy is present. In instances of seminiferous tubule atrophy, morphometric analysis is necessary to confirm whether a compound is producing diffuse Leydig cell hyperplasia. In addition, slight increases in serum E2 levels may also be observed with potent antiandrogens. In the female battery, there may be slight increases in uterine stromal cell proliferation with potent androgen receptor antagonists (Table 9) ; however, it is unlikely that weaker compounds would elicit the same response.
In the in vivo female battery, KETO administration increased serum PRL levels and uterine epithelial cell height. These increases were unexpected and the mechanisms for these increases are unknown. Uterine epithelial cell height can be affected by mechanisms other than estrogenicity (e.g., dopamine regulators and glucocorticoids) (O'Connor et al, 1996) , and therefore it is less specific than uterine stromal cell proliferation for detecting compounds with estrogen agonist/ antagonist activity or dopaminergic modulators. The increase in serum PRL levels appears spurious since there is a lack of concordance in the in vivo male battery. This demonstrates the value of having redundancy in endpoints. While it is possible that the increase in serum PRL was a stress-induced response (Krulich et al, 1974; Seggie and Brown, 1975) , it seems unlikely since our control values are consistent with those measured with the other four controls. Furthermore, serum PRL levels for the control group were similar to those observed from rats whose blood was collected using an indwelling catheter (Cook et al., 1997a) . Hence, the increase in PRL was considered a false-positive response for KETO. However, the lack of concordance in the in vivo male battery would lead one to conclude that KETO is not a dopaminergic modulator. In the in vivo male battery, responses to KETO included decreased weights for all androgen-dependent tissues (epididymis, seminal vesicles, prostate, and accessory sex gland unit), hormonal alterations (decreased T and DHT and increased LH and FSH), and microscopic alterations of the testis (spermatid retention). KETO inhibits T biosynthesis by binding to the heme iron of the three cytochrome P 450 isozymes of the testosterone biosynthetic pathway (Feldman, 1986; Morita et al, 1990 ). Therefore, Leydig cells are unable to produce sufficient quantities of T. As a result, LH and FSH release from the pituitary are increased to stimulate T production. Secondary to the decrease in T, serum DHT levels are also decreased. In the in vitro YTS, KETO does not show activity in the three receptor systems examined. Therefore, the expected pattern for a testosterone biosynthesis inhibitor would be decreased weights for all androgen dependent tissues in the in vivo male battery, coupled with hormonal alterations (decreased T and DHT and increased LH and FSH) and mild spermatid retention (Table 8) . No changes in any of the endpoints would be expected in the in vivo female battery or the in vitro YTS (Tables 7 and 9 ).
The pattern of the responses observed with FIN, a 5 areductase inhibitor, were characteristic of the responses expected using the Tier I battery. In the in vivo female battery, no changes were observed in any of the endpoints. In the in vivo male battery, responses to FIN included decreased seminal vesicle and ASG unit weight, and hormonal alterations (decreased DHT, and increased PRL and LH). FIN inhibits 5a-reductase, the enzyme that metabolizes T to DHT (Rittmaster, 1994) . As a result, tissues in which DHT acts as the primary androgen, such as the prostate gland and seminal vesicles, have decreased androgenic stimulus, resulting in decreased weights (Rittmaster, 1994) . As a result of the decreased DHT levels, serum LH levels are increased (Rittmaster, 1994) . The reason for the increase in serum PRL levels is unknown; however, the decreased androgenic stimulus (decreased DHT levels) could potentially enhance PRL levels via a net increase in estrogenic stimulus. Alternatively, since serum E2 levels are slightly elevated (not statistically significant), it is possible that the increased PRL levels may be a secondary effect due to enhanced aromatization of T within the brain. In the in vitro YTS, FIN did not show activity in the three receptor systems examined, consistent with previously published data using competitive receptor binding assays (Laroque et al., 1994; Rasmusson et ai, 1986) . However, FIN inhibited binding of DHT to the AR and 17/3-estradiol to the ER in YTS competition assays (Figs. 4A and 4B, respectively) . FIN has been reported to inhibit complex formation between the AR-ligand complex and the DNA promoter, resulting in attenuated transcriptional activity (Wang et al, 1997) . The data in the YTS ER and AR competition assays suggest that FIN may have some antagonist activity due to decreased transcriptional activation as a result of decreased receptor-ligand-promoter complex formation. While FIN was active in the YTS competition assay, this is probably unique to FIN and not common to all 5a-reductase inhibitors. Therefore, the expected pattern for a 5a-reductase inhibitor would be decreased ASG weights in the in vivo male battery coupled with hormonal alterations (decreased DHT and increased LH) ( Table 8) . No changes in any of the endpoints would be expected in the in vivo female battery or the in vitro YTS (Tables 7 and 9 ).
The pattern of the responses observed with ANA, an aromatase inhibitor with no other intrinsic hormonal activities (Dukes et al., 1996) , were characteristic of the responses expected using the Tier I battery. In the in vivo female battery, no changes were observed in any of the endpoints. This was expected since circulating levels of E2 are very low in the ovariectomized female rat, although measurable levels of serum E2 are present, presumably due to adrenal synthesis. In the in vivo male battery, responses to ANA included decreased ASG unit and seminal vesicle weights and decreased serum E2 levels due to inhibition of aromatase, the enzyme that metabolizes T to E2 (Dukes et al, 1996) . The mechanism for the decrease in seminal vesicle weight is unclear, and is inconsistent with previous data for ANA (Dukes et al, 1996) . However, the decrease in ASG unit and seminal vesicle weights is a pattern that has been replicated in our laboratory using two proprietary compounds with aromatase inhibition activity (data not shown). In the in vitro YTS, ANA does not show activity in the three receptor systems examined. Therefore, the expected pattern for a selective aromatase inhibitor would be decreased ASG unit and seminal vesicle weights and decreased serum E2 levels in the male battery (Table 8) . No changes in any of the endpoints would be expected in the in vivo female battery or the in vitro YTS (Tables 7 and 9 ).
Utility of the Tier I Battery for Identifying Compounds That Alter Thyroid Homeostasis
Chemicals that alter thyroid function can act by altering synthesis, release, transport, or metabolism of thyroid hormones, or by acting as thyroid hormone receptor agonists or antagonists (reviewed in Capen, 1997) . Two endpoints that are routinely used for identifying compounds that alter thyroid function are thyroid hormone levels and histopathology of the thyroid gland. With the increasing number of commercially available rat hormone assay kits, examining thyroid hormone homeostasis is a quick and easy method to identify compounds that alter thyroid function; however, these data require cautious interpretation. Many factors can affect thyroid hormone levels, including diet, stress, age, and circadian rhythm (reviewed in Capen, 1997; and, Hill et al, 1989) . Furthermore, detection of small changes in thyroid hormone levels can be confounded due to normal variability between animals (reviewed in Davies, 1993) .
The American Thyroid Association recommends determination of serum TSH and free T 4 levels as the standard measure of thyroid function in humans (Surks et al, 1990) . In humans, total T 4 levels are not recommended as an endpoint for determining alterations in thyroid hormone levels since total concentrations of T 4 can be affected by thyroxine binding globulin (TBG), a serum binding globulin that can be altered by many disease states and Pharmaceuticals (reviewed in Capen, 1997) . However, since rodents do not have TBG, total T 3 , total T 4 , and TSH are routinely used for evaluating thyroid hormone homeostasis (reviewed in Capen, 1997; Biegel et al, 1995; Barter and Klaassen, 1992; McClain et al, 1989; Bartomsky, 1977) . One consistent finding with all thyroid tumorigens is a chronic hypersecretion of TSH (reviewed in Capen, 1997; Davies, 1993; Hill et al, 1989) . The typical hormonal pattern for compounds that induce follicular cell hypertrophy/hyperplasia in rodents is decreased serum levels of total T 3 and T 4 and increased serum TSH levels (Biegel et al, 1995) .
In the Tier I battery, thyroid hormone analyses {in vivo male battery only) and microscopic evaluations of the thyroid gland {in vivo male and female battery) were performed for each test compound in order to identify compounds that target the thyroid gland. The goal was to evaluate the utility of these endpoints as a screening battery for identifying compounds that have the potential to alter thyroid function. The expectation was that none of the test compounds described in this report would alter thyroid function, since none of the test compounds induce follicular cell hypertrophy/hyperplasia in long-term rodent studies {Physician 's Desk Reference, 1996) . Surprisingly, thyroid hormone levels were affected by all five compounds (Table 6 ). It is hypothesized that the decreases in T 3 and T 4 observed with FLUT and KETO, and the subsequent increase in TSH levels observed with KETO, may be due to liver enzyme induction based on the increases in relative liver weights observed with these two test compounds (Table 4) . However, KETO was the only compound that displayed the expected hormonal pattern for a compound that targets the diyroid gland; namely, decreased serum T 3 and T 4 levels and increased TSH levels (Biegel et al, 1995) . KETO has been shown to affect thyroid hormone levels in humans, although it does not induce thyroid hypertrophy/hyperplasia in long-term rodent assays {Physician 's Desk Reference, 1996) . For this reason, these changes probably represent modulation (compensated changes that produce no tissue structural changes) rather than disruption (changes that cannot be compensated and produce tissue structural changes) of the thyroid axis. The mechanisms for the changes in thyroid hormone levels for ICI, FIN, and ANA are unclear; however, it is hypothesized that they may be due to other factors (reviewed in Capen, 1997; Hill et al, 1989) .
Data interpretation based solely on changes in thyroid hormone levels would incorrectly identify all five compounds as potential thyroid gland tumorigens; however, no microscopic changes of the thyroid gland were observed with any of the test compounds in the male or female in vivo battery or in longer duration studies {Physician's Desk Reference, 1996) . Therefore, thyroid hormone analyses used in conjunction with microscopic evaluation of the thyroid gland appears prudent when screening for compounds that target the thyroid gland. In support of this, at the 1997 thyroid workshop entitled Screening Methods for Chemicals That Alter Thyroid Hormone Action, Function and Homeostasis, thyroid gland histopathology was determined to be the most reliable parameter for the detection of compounds that affect thyroid function. Based on these data, the recommended endpoints for inclusion in the Tier I battery would be to use microscopic evaluation of the thyroid gland as the primary diagnostic tool for identifying compounds that have the potential to alter thyroid function, coupled with increases in serum TSH levels, and decreases in T 3 and T 4 , where the magnitude of the change should be in excess of twofold. One concern regarding the inclusion of thyroid gland histopathology is that it is unclear whether a 2-week exposure, similar to that currently being evaluated, is long enough to detect weak-acting compounds that target the thyroid gland. We have successfully used thyroid gland histopathology coupled with thyroid hormone analyses to identify one compound that alters thyroid function, and found 2 weeks to be sufficient for detecting compound-induced microscopic changes of the thyroid gland (Biegel et al, 1995) . Furthermore, we have compared the sensitivity of thyroid follicular cell proliferation and histopathology and found histopathology to be more sensitive than cell proliferation as an endpoint for compounds that alter thyroid function (unpublished data). Future studies will examine the ability of the Tier I screening battery to identify compounds that are known to target the thyroid gland, such as phenobarbital and propylthiourea. These data will facilitate guidance around the magnitude of hormonal change necessary to consider a compound to be a thyroid toxicant.
Conclusions
In summary, this Tier I screening battery correctly identified six compounds with distinct endocrine activities including an estrogen receptor agonist (O'Connor et al, 1998) , a pure estrogen receptor antagonist, an androgen receptor antagonist, a testosterone biosynthesis inhibitor, a 5a-reductase inhibitor, and an aromatase inhibitor, as well as several other compounds that are not pharmaceutical products such as methoxychlor (a proestrogen) (Cook et al., 1997b) , bisphenol A (a weak estrogen receptor agonist) (Cook et al., 1997b) , linuron (an androgen receptor antagonist) (Cook et al, 1993) , atrazine and cyanazine (dopaminergic modulators) (Cook et al, 1997a) , a placebo pellet with estrogenic activity (O'Connor et al., 1997) , and three proprietary compounds (identified as being an aromatase inhibitor, mixed testosterone/aromatase inhibitor, and androgen receptor antagonist) (unpublished data). Furthermore, based on the results obtained with each compound, we have developed a "fingerprint" for six distinct endocrine activities against which compounds with unknown activities can be compared. While not all endpoints are always completely predictive for a particular endocrine activity, and potency differences could also contribute to differences in "fingerprint" profiles for unknown compounds, the built-in redundancy coupled with the sensitive endpoints of the proposed Tier I battery should decrease the number of false positive and negative responses.
The goal of our ongoing validation of our Tier I screening battery is to identify which endpoints are predictive for each type of endocrine activity, so that future screening models can be tailored to be both cost effective and comprehensive. In addition, by examining each of the model test compounds, a "fingerprint" can be developed for each endpoint against which compounds with unknown activity can be compared. In this respect, certain endpoints that are currently incorporated into the Tier I screening battery may not add value to the screen due to a lack of specificity or sensitivity, difficulty in data interpretation, or simply a lack of additional information above what is already available from the battery. Currently, we believe that several endpoints would be considered unnecessary in a future Tier I screening battery. In the Tier I female battery, these endpoints include uterine estrogen and progesterone receptor levels (lack of specificity and difficulty in data interpretation). Additional work will help determine the usefulness of uterine epithelial cell height, serum FSH and LH levels, and microscopic evaluation of the thyroid gland in a final Tier I-type screen. In the Tier I male battery, the unnecessary endpoints include weights for the individual components of the ASG unit (minimal value added), serum FSH levels (low sensitivity), and microscopic evaluation of the epididymis (minimal added value). Studies are ongoing with nine additional compounds to examine the responses obtained with other EACs possessing different endocrine activities to further validate this tiered-testing approach and to allow further assessment of which endpoints should be included in a final Tier I-type screen. Clearly, no screening battery is foolproof and unexpected findings will occur. However, in most instances, the built-in redundancy of Tier I (i.e., internal consistency across the three components), coupled with searching the published literature, should allow one to distinguish between true biologic responses versus spurious findings.
